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Abstract
Pneumonia virus of mice (PVM) causes bronchiolitis and pneumonia in mice. Infection is associated with high levels of viral replication in the
lungs and results in the functional inactivation of pulmonary virus-specific CD8 T cells. Due to its similarity to severe human respiratory syncytial
virus (RSV) infection, PVM infection in mice has been proposed as an alternative RSV model. Here, we have delineated the minimal requirements
for protective T cell immunity in the PVM model. Immunization with a CD8 T cell epitope from the PVM phosphoprotein P, combined with the
ovalbumin (OVA) CD4 T cell epitope, did not confer protective immunity against lethal PVM challenge, suggesting a possible role of cognate
CD4 T cell immunity. To determine the role of PVM-specific CD4 T cell responses, we mapped a PVM CD4 T cell epitope in the glycoprotein G,
using a panel of overlapping peptides. Although immunization with this epitope provided some protection, solid protective immunity was only
observed after immunization with a combination of the PVM-specific CD4 and CD8 T cell epitopes. Analysis of post-challenge T cell responses in
immunized mice indicated that G-specific pulmonary CD4 T cells displayed a mixed Th1/Th2 phenotype, which was characterized by the
presence of both IL-5 and IFN-γ secreting cells, in the absence of overt pathology.
© 2007 Elsevier Inc. All rights reserved.Keywords: Pneumonia virus of mice; CD4 T cells; Protective immunity; Th2 responses; Intereleukin-5Introduction
Pneumonia virus of mice (PVM) belongs to the Pneumo-
virinae subfamily of the paramyxoviruses and is a natural
pathogen for mice. PVM is highly related to the human and
bovine respiratory syncytial viruses (RSV) and to the human
metapneumovirus, and has been proposed as a tractable model
for severe RSV infection (Rosenberg et al., 2005). PVM causes
bronchiolitis and pneumonia in mice, both of which resemble
human RSV infection. Contrary to RSV in mice, PVM infection⁎ Corresponding author. Present address: Tumour Immunology Group, School
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doi:10.1016/j.virol.2007.06.002results in very high levels of virus production in the lungs (Cook
et al., 1998). As such, PVM infection in mice could provide a
useful alternative model for RSV vaccine development. An
attractive feature of this model is that it can be used to delineate
the requirements of Pneumovirus protective immunity in the
context of a natural virus-host relationship. However, only
limited data exist at present on the nature of the antiviral T cell
responses and the further development of PVM as an alternative
model for human RSV requires a better understanding of these
responses and their targets.
We have recently shown that PVM infection in BALB/c
mice results in a strong CD8 T cell response that is directed
against epitopes in the phosphoprotein (P261–269), matrix
protein (M43–51) and fusion protein (F304–312) (Claassen et al.,
2005). PVM-specific CD8 T cells in the lungs of PVM-infected
mice display a partially inactivated phenotype: only 10–20% of
P261-specific CD8 T cells are capable of producing IFN-γ or
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is similar to the partially inactivated phenotype of RSV-specific
CD8 T cells in the lungs of RSV-infected mice (Chang and
Braciale, 2002). However, data on the antiviral CD4 T cell
responses are still lacking. A further study of the PVM-specific
CD4 T cell response is important for the following three
reasons. First, identification of a CD4 Tcell epitope is needed in
order to determine the requirements for PVM protective
immunity. Second, CD4 T cell responses most likely play a
key role in the Th-2 biased T cell responses observed in mice,
cattle and in humans after RSV infection (Openshaw et al.,
2001; Varga and Braciale, 2002), and translation of these results
to the PVM model requires the identification of epitopes. In
fact, PVM infection has the capacity to prime mice for
respiratory allergy (Barends et al., 2004) and is associated
with eosinophilia (Domachowske et al., 2000), indicating a
potential Th-2 bias of the virus-induced CD4 T cell response.
Third, it is possible that CD4 T cell responses play a role in the
functional inactivation of antiviral CD8 T cells. Support for this
possibility is provided by the fact that CD8 T cell functionality
can be rescued by IL-2 in RSV-infected mice (Chang et al.,
2004).
To investigate these issues, it was essential to first identify
PVM CD4 T cell epitopes. For the purpose of epitope mapping,
we focused on the G protein because the major immunopatho-
genic CD4 T cell epitope in RSV-infected mice is located in the
RSV G protein (Varga et al., 2000). Herein, we report the
mapping of an epitope at the C-terminus of the protein. We
show that immunization with this CD4 T cell epitope provided
partial protection against lethal PVM challenge, but that the
protective efficacy could be enhanced by including the P261
CD8 T cell epitope in a peptide vaccine. PVM-specific CD4 T
cells appear to have a mixed Th-1/Th-2 phenotype, similar to
RSV G-specific CD4 T cells (De Graaff et al., 2004; de Waal et
al., 2004; Varga et al., 2001; Varga et al., 2000). In vitro
stimulation of pulmonary lymphocytes from infected mice with
the PVM G peptide resulted in the secretion of both IFN-γ and
IL-5.
Results
Identification of a CD4 T cell epitope in the PVM G protein
In order to study the role of CD4 T cell responses in the
generation of protective immunity, we set out to identify PVM-
specific CD4 T cell epitopes. Since the major RSV CD4 T cell
epitope was identified in the G protein (Varga et al., 2000), we
focused our epitope mapping effort on its PVM counterpart.
Thus, we obtained a set of 78 overlapping 15-mer peptides
spanning the entire PVM G protein (396 amino acids) and used
these peptides to stimulate splenic lymphocytes from PVM-
infected mice (50 pfu, day 8 post infection). IFN-γ ELISPOT
responses were considered positive if they exceeded the average
value plus two standard deviations. Based on an average
number of spots of 5.2 and a standard deviation of 6.6, resulting
in a cutoff of 18 spots (indicated in Fig. 1a), we identified
positive responses with peptides 77 and 78 (42 and 30 spots/106splenocytes, respectively), as well as against peptide 70 (26
spots) (Fig. 1a). Peptide 70 had 18 spots, which is at the cutoff
value. The highest responder, peptide 77, encompasses residues
381–395 (PYWCPMLQLFPRRSN), at the C-terminus of the G
protein. The preceding peptide 76 (residues 376–390) did not
induce any response. To confirm these results and to determine
whether the G381–395 peptide indeed harbored a CD4 T cell
epitope, we harvested pulmonary lymphocytes at days 8 and 28
post infection (p.i.) and stimulated these cells with peptide 77
(G381–395). Responses were visualized by intracellular IFN-γ
staining. Unfortunately, we found that the background IFN-γ
response in unstimulated cells at day 8 p.i. was high (data not
shown), thereby reducing the sensitivity of the assay. Since
analysis at day 28 resulted in considerably less background
signal, we focused our experiments on this timepoint. At day 28
p.i., we found that 0.06–0.08% of total pulmonary CD4 T cells
responded to peptide G381–390 (Fig. 1b). No CD8 T cells
responded to this peptide (data not shown). Thus, these data
show that peptide 77 encompasses a CD4 T cell epitope. The
G381–395-specific response represented only a minor proportion
of the total numbers of activated (CD11ahi CD62Llow CD43hi)
(Cauley et al., 2002; Hogan et al., 2001) CD4 T cells in the
lungs at days 28 post infection (42% CD62Llow CD4 T cells,
and 25% CD11ahigh CD43high CD4 T cells, versus 19% and
3.5% in naive mice, respectively) (Fig. 1c).
Role of PVM-specific CD4 T cell memory in protective
immunity
Having identified a PVM-specific CD4 T cell epitope, we
evaluated its importance in protective immunity. BALB/c mice
were immunized with combinations of the newly found G381
peptide and the previously identified P261 CD8 T cell epitope,
all emulsified in IFA. Four groups of mice were used. Group 1
was immunized with only the CD4 T cell epitope, group 2 was
immunized with a combination of the CD4 and CD8 T cell
epitopes, group 3 was immunized with a combination of the
CD8 T cell epitope and the CD4 T cell epitope from ovalbumin
(OVA323–339) and group 4 was mock-immunized with PBS. The
OVA323–339 CD4 T cell epitope was included in the IFA
emulsion to provide T cell help (van der Most et al., 1996),
which is essential to prevent the generation of ‘helpless’ CD8 T
cells after challenge (Janssen et al., 2003). Mice were
challenged with PVM 4 weeks later. As the primary read-outs
for protective immunity, we used survival time. As shown in
Fig. 2, immunization with the CD4 T cell epitope provided
partial protection, 9/16 mice survived. This result was
significantly better than the PBS control group, in which 3/20
mice survived (P=0.022). Combining the G381 CD4 T cell
epitope with the P261 CD8 T cell epitope provided the best
protection: this combination protected 17/20 mice from lethal
infection (Pb0.0001, compared to PBS group). In all cases, we
found that protective immunity prevented the severe symptoms
that were associated with lethal infection, such as obstructed
breathing and nasal mucus formation (data not shown),
indicating a much less severe pathology. Although protection
was partial, it is clear that the efficacy of the combination
Fig. 1. Identification of a PVM-specific CD4 T cell epitope. (a) IFN-γ ELISPOT analysis of splenocytes obtained at day 8 after PVM infection (50 pfu). Cells were
stimulated with a set of overlapping 15-mer peptides spanning the entire G protein. Stimulations were done with individual peptides. (b) Pulmonary lymphocytes were
harvested as described in the Materials and methods at day 28 after PVM infection (500 pfu, respectively) and stimulated with peptide 77 (upper panels) or were
stimulated with a negative control peptide (lower panels). Responses were visualized by intracellular IFN-γ staining. Representative data are shown. (c) Pulmonary
lymphocytes were harvested from PVM-infected mice (day 8 and day 28 p.i.) or from naive mice and stained with antibodies against CD4, CD43, CD62L and CD11a.
Data shown were gated on forward and side scatter (upper panel) or on forward/side scatter and on CD4+ cells (lower panel).
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epitope alone (P=0.0026). A trend towards significance in the
two-tailed t test (P=0.054) was observed for the difference
between the G381+P261 group and the G381 group.
Functional characterization of PVM-induced CD4 T cell
responses
To determine whether PVM infection would also result in the
generation of a Th-2 biased memory response, and to study the
effect of immunization on this potential response, we analyzed
the cytokine profile of PVM-specific CD4 T cell responses insurviving mice at day 28 post-challenge by IFN-γ and IL-5
ELISPOT assays. It is obvious that this analysis results in a
survivor bias. However, our specific question dealt with the
nature of the CD4 T cell response rather than its relation with
protective immunity. As a control, P261-specific responses were
included.
As shown in Fig. 3, we observed that the levels of P261- or
G381-specific T cells in surviving mice correlated with the
presence of the epitopes in the vaccines, consistent with a
vaccine-primed prime-boost effect. Thus, the highest P261 and
G381 responses were measured in mice that had been vaccinated
with the respective peptides. This was observed in the lung as
Fig. 2. Protective immunity. Kaplan–Meier survival plot, indicating the efficacy
of P261 (‘CD8’), G381 (‘CD4’) and P261+G381 (‘CD4+CD8’) T cell immuniza-
tion. Mice were immunized with peptides emulsified in IFA (n=16 for P261
+OVA323, n=12 for G381 only, and n=16 for P261+G381), or with PBS in IFA
(mock, n=16), and challenged 4 weeks later. Percentage survival after PVM
challenge (500 pfu) of peptide- or mock-immunized mice is shown (⁎P=0.022;
⁎⁎P=0.0026; ⁎⁎⁎Pb0.0001).
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responses was detected in the lungs of infected mice by
ELISPOT. G-specific IL-5 responses were readily identified in
all mice in which IFN-γ producing G381-specific T cells were
detected (Fig. 3). Consistent with the G381-specific IFN-γ
ELISPOT data, the strongest IL-5 responses were measured in
PVM survivors that had been immunized with G381–395 only or
with the combination of G381 and P261.
While analyzing T cell responses in PVM challenge
survivors, we observed that surviving mice that had been
immunized with the combination of the P261 +OVA323
peptides harbored IFN-γ-producing OVA-specific T cells not
only in their spleens (data not shown) but also in their lungs
(Fig. 4). This suggests that OVA-specific memory cells were
recruited into the lungs during the antiviral response.
Surprisingly, we found that pulmonary OVA-specific T cells
also produced IL-5 after PVM challenge (Fig. 4). Thus,
pulmonary OVA-specific T cells, apparently recruited into the
lungs during PVM infection, appeared to display the same
mixed Th1/Th2 phenotype as the antigen-driven G381-specific
response (Fig. 3).
CD4 T cell memory does not prevent functional inactivation
CD8 T cells
Finally, we used the CD4 G epitope to address the question
whether vaccine-induced PVM-specific memory CD4 T cells
could rescue the functionality of post-challenge pulmonary
CD8 T cells. To test this, P261-specific CD8 T cells at 28 days
post-challenge were quantitated by P261 pentamer staining
(Claassen et al., 2005) and their functionality was assessed by
intracellular IFN-γ staining after peptide stimulation. Con-
sistent with our previous study, we found that only 10–20% of
P261-specific CD8 T cells produced IFN-γ after peptide
stimulation (Claassen et al., 2005) and that IFN-γ+ responses
did not exceed 1.4% of all pulmonary CD8 T cells (Fig. 5). Asshown in Fig. 5, the presence of a PVM-specific recall CD4 T
cell response did not change this ratio between pentamer-
positive and IFN-γ producing cells (Fig. 5). Irrespective of the
vaccine composition used, i.e., CD8 or CD4 T cell epitopes
only, CD4/CD8 combined or mock-immunized, we observed
4–10-fold higher frequencies of pentamer-staining cells than
IFN-γ+ cells (Fig. 5). These data suggest that the better
protective efficacy of the P261+G381 peptide vaccine cannot
be explained by the rescue of functional pulmonary CD8 T
cells after PVM challenge. However, frequencies of P261-
specific CD8 T cells were higher in CD4+CD8 immunized
mice (Fig. 5).
Discussion
In the present study, we have mapped a CD4 T cell epi-
tope in the PVM glycoprotein G, spanning residues 381–395
(PYWCPMLQLFPRRSN). The G381–395 peptide exclusively
stimulated CD4 T cells and not CD8 T cells. However, we
cannot yet exclude that the G381–395 peptide might contain an
overlapping B cell epitope. The sequence of peptide G381–395
has no significant homology with any other protein. Identifica-
tion of this epitope allowed us to define the requirements for
protective immunity against lethal PVM challenge, and
characterize the Th-1/Th-2 phenotype of the PVM CD4 T cell
response.
Protective immunity
The data presented herein indicate that a minimal
immunization protocol with two T cell epitopes, such that
both CD4 and CD8 T cell responses are primed, provides
protection in the stringent PVM challenge model. Protective
immunity against PVM challenge was also described recently
by Ellis et al., using mucosal vaccination with attenuated virus.
Protective immunity was associated with the presence of
neutralizing antibodies in the serum after vaccination (Ellis et
al., 2007). Our data revealed that immunization with the
CD4 T cell epitope only provided partial protection, whereas
immunization with solely the CD8 epitope failed to protect
mice. Thus, protective immunity most likely requires both
CD4 and CD8 memory T cells. However, we cannot yet
exclude that either peptide could induce antibody responses,
which could contribute to immunity. Perhaps the most
intriguing possibility would be when the G381–395 peptide
would harbor overlapping CD4 T cell and B cell epitopes. This
is currently under investigation.
A conspicuous feature of our experiments was that
immunization with the P261 CD8 Tcell epitope, when combined
with non-cognate CD4 help, failed to induce protective
immunity. It could be argued that the efficacy of P261 peptide
vaccination could be improved by using multiple immuniza-
tions. However, the point of this study is that the protective
efficacy of a relatively weak vaccination method (single IFA-
peptide vaccination) is enormously improved when a PVM
CD4 T cell epitope is included. In fact, a recent study, using a
fusion protein of the P261 peptide with the detoxified ricin B
Fig. 3. T cell responses in immunized PVM survivors at day 28 post-challenge infection, as measured by IFN-γ or IL-5 ELISPOT. The immunization protocols are
indicated at the bottom of each graph. Lymphocytes were stimulated with peptide P261 (a, b), G381 (c–f) or were left unstimulated. Background was subtracted to yield
the number of specific spots. (a) P261-specific IFN-γ responses in the spleen (⁎P=0.0236; ⁎⁎⁎Pb0.0001). (b) P261-specific IFN-γ responses in the lungs
(⁎⁎P=0.0033; ⁎P=0.0139). (c) G381-specific IFN-γ responses in the spleen (⁎P=0.016; ⁎⁎P=0.0095). (d) G381-specific CD4 IFN-γ responses in the lungs
(⁎⁎P=0.007). (e) G381-specific IL-5 responses in the spleen (⁎P=0.016). (f) G381-specific IL-5 responses in the lungs (⁎P=0.0291; ⁎⁎P=0.010).
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boosting (Grimaldi et al., 2007). Thus, we hypothesize that
protective PVM immunity is a matter of quality, not quantity.
Why is cognate CD4 T cell memory so important for
protective immunity? Conceivably, the CD4 T cell recall
response at the time of PVM infection could accelerate
development of CD8 T cell responses or boost post-challenge
B cell responses, leading to a more rapid production of
neutralizing antibodies. As mentioned before, we cannot yet
exclude that the G381–395 peptide itself induced an antiviral B
cell response. Alternatively, CD4+ effector T cells could play arole independent of antibodies or CD8 T cells, possibly via
IFN-γ (Hogan et al., 2001; Zhong et al., 2001).
Mixed Th-1/Th-2 phenotype of the G-specific response
The G381-epitope induces production of IFN-γ, as well as the
Th2-cytokine IL-5. This mixed Th1/Th2 cytokine response
pattern resembles the RSV G-specific CD4 T cell responses
observed in humans (De Graaff et al., 2004; de Waal et al.,
2004) and mice (Varga et al., 2000). Increased frequencies of
IL-5 producing G381-specific CD4 T cells were observed in
Fig. 4. Pulmonary OVA323-specific mixed Th-1/2 responses, after immunization
with CD8+OVA (left panel) or CD4+CD8 (right panel). IFN-γ ELISPOT
responses were measured at day 28 post infection in immunized mice, as
indicated. Lymphocytes were stimulated with either the G381 peptide or the OVA
peptide, as indicated, or were left unstimulated. Note that OVA-specific Th-1
and Th-2 cells are only detected in CD8+OVA immunized and PVM-challenged
mice.
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or with the protective G381/P261 combination. Thus, pulmonary
IL-5 production can be involved in protective immune
responses. Indeed, IL-5 plays an crucial role in the production
of IgA antibodies in mucosal tissues (Moon et al., 2004).
Similar to RSV in mice (Varga et al., 2001) and BRSV in cattle
(Antonis et al., 2003, 2006), Th-1 and Th-2 responses co-exist
during PVM infection. These observations are consistent with
observations that pulmonary Th-2 responses in fact depend on
Th-1 responses (Randolph et al., 1999). A salient detail in our
findings is that OVA-specific CD4 T cells were also recruited
into the lungs. This recruitment of non-specific CD4 T cells is
consistent with previously reported data (Stephens et al., 2002;Fig. 5. Vaccine-induced G381-specific CD4 memory T cells do not prevent P261-specif
MHC class I pentamer staining (upper row) and by intracellular IFN-γ staining fol
Representative data of 3–4 mice are shown. No responses were measured in unstimChapman et al., 2005). These cells displayed a mixed Th1/Th2
phenotype. Interestingly, Stephens and coworkers described
that non-specific recruitment of Th-2 biased cells into the lungs
is also driven by a Th-1 inflammatory response (Stephens et al.,
2002). This could provide an explanation for the presence of IL-
5-secreting OVA-specific cells that persist in the lungs after
PVM infection. The presence of such Th1/Th2 memory CD4 T
cells in the lungs after PVM infection could have profound
implications for our understanding of post-virus bronchial
hyperreactivity phenomena.
Pulmonary PVM-specific CD8 T cells are not rescued from
inactivation by recall CD4 T cell responses
The inclusion of the CD4 epitope in the vaccine did not
rescue PVM-specific pulmonary CD8 T cells from functional
inactivation. Thus, the eventual inactivation of PVM-specific
CD8 T cells does not impede protective immunity, consistent
with a recent study showing that attenuated PVM would confer
protective immunity in IFN-γ receptor deficient mice (Ellis et
al., 2007), indicating that IFN-γ itself may not be a critical
effector molecule. Similarly, functionally inactivated M2-
specific CD8 T cells were observed in vaccinia virus-M2-
immunized and RSV-infected mice (Chang and Braciale, 2002).
The key question now is how virus-specific pulmonary CD8 T
cells are inactivated, while involved in a protective response.
We assume that our epitope vaccines do not induce neutralizing
antibodies, which would imply that the virus will undergo some
initial replication and will trigger T cell activation (Ostler et al.,
2001) in immunized animals. Most likely, this early viral
replication suffices to inactivate antiviral CD8 T cells. Asic CD8 Tcell inactivation in the lungs. P261-specific responses were measured by
lowing peptide stimulation (lower row). Mice had been immunized as shown.
ulated cells.
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inhibitory B7 family members on lung epithelium (Stanciu et al.,
2006). This, in turn, could induce functional inactivation of CD8
T cells through PD-1, as shown recently (Barber et al., 2006).
The magnitude of the pulmonary CD4 T cells response
Responses against the G381 epitope were relatively small. In
all cases, we found that frequencies of G381-specific CD4 T
cells were much lower than frequencies of activated (CD11ahi
CD43hi CD62Llow) (Cauley et al., 2002; Hogan et al., 2001)
CD4 T cells. There are several possible explanations for this.
First, the PVM proteome may harbor additional, and possibly
more dominant, CD4 T cell epitopes. Second, it is possible that
not all pulmonary G381-specific CD4 T cells produce IFN-γ.
An exciting possibility is that CD4 T cells are functionally
inactivated, similar to the CD8 T cells. In fact, human alveolar
macrophages have been reported to inactivate antigen-specific
CD4 T cells (Blumenthal et al., 2001). Also, RSV-infected
dendritic cells have a profound negative effect on CD4 T cell
proliferation and cytokine production (de Graaff et al., 2005),
which appears to be mediated through the combined action of
IFN-α and IFN-λ(Chi et al., 2006). It is tempting to speculate
that PVM also infects dendritic cells, with similar negative
effects on the antiviral CD4 T cell response. Third, bystander
CD4 T cells may be recruited into the inflamed lungs. It has
been shown for Sendai virus that this indeed happens during
the acute antiviral response (Chapman et al., 2005; Stephens et
al., 2002), and our observation that OVA-specific CD4 T cells
are recruited into the lungs is consistent with this. However,
arguing against a major role of bystander activation is the fact
that the phenotype of the pulmonary CD4 T cells after PVM
infection (CD11ahigh CD62Llow CD43high) closely resembles
the phenotype of MHC class II tetramer-positive Sendai virus-
specific CD4 T cells in the lungs of Sendai virus-infected mice
(Cauley et al., 2002). This suggests that the CD11ahigh
CD62Llow CD43high phenotype truly identifies antigen-specific
CD4 T cells. However, we cannot yet exclude any of these
possibilities and it is possible that all three contribute to the
discrepancy between G381-specific and activated CD4 T cell
frequencies.
Materials and methods
Mice, virus and infections
Four- to six-week-old female BALB/c ByJIco mice were
obtained from Charles River Nederland (Maastricht, The
Netherlands). Mouse-passaged stocks of PVM strain J3666
(Cook et al., 1998) (∼1×105 PFU/ml) were provided by Dr.
Andrew Easton and grown as described (Claassen et al., 2005).
Viral stocks were defrosted and diluted in PBS immediately
prior to intranasal inoculation (50 μl; 50–500 pfu for PVM)
under light ether anesthesia, as described previously (Claassen
et al., 2005). The mouse study protocol was approved by the
Animal Ethics Committee of the Veterinary Faculty of the
University of Utrecht.Peptides
Overlapping 15-mer peptides spanning the entire PVM G
protein (Thorpe and Easton, 2005) were synthesized, resulting
in a total of 78 peptides. All peptides were synthesized by the
Peptide and Protein Facility (Department of Immunology,
Utrecht University).
Peptide immunization
Peptides G381–395 (PYWCPMLQLFPRRSN), P261–269
(CYLTDRARI) (Claassen et al., 2005) and OVA323–339 (KIS-
QAVHAAHAEINEAG) (all at 50 nmol/mouse) were emulsified
in Incomplete Freunds Adjuvant (IFA) in the appropriate
combinations. The negative control formulation consisted of an
emulsion of PBS and IFA. Four week-old BALB/c mice were
immunized by subcutaneous injection (50 μl) at the base of the
tail. After 28 days, the mice were challenged with 500 PFU of
PVM strain J3666. Challenged mice were observed for a
maximum of 28 days and then sacrificed for T cell analysis.
Sampling and tissue preparation
Mice were sacrificed by intraperitoneal (i.p.) injection of
sodium pentobarbital. Before recovery, the lungs were per-
fused with PBS containing 50 units/ml heparine. Lungs and
spleen were recovered under aseptic conditions and trans-
ferred to 2 ml of prechilled RPMI 1640 medium (Invitrogen
Life Technologies). Lungs were mechanically minced and
incubated in PBS containing collagenase (2.4 mg/ml; Roche
Applied Science, Roche) and DNAase (1 mg/ml; Roche
Applied Science), for 20 min at 37 °C. Single-cell suspen-
sions were prepared from the pre-treated lungs and spleens by
passage through cell strainers. Spleen cells were depleted of
erythrocytes by treatment with a buffered 0.83% ammo-
niumchloride solution.
In vitro stimulations
For intracellular cytokine staining, lung and spleen
lymphocytes (1×106) were stimulated in 96-well flat-bottom
plates in 200 μl RPMI (Invitrogen Life Technologies),
containing 10% FCS, 1% L-glutamine, 5 μg/ml peptide and
10 μg/ml Brefeldin A (Sigma-Aldrich) for 6 h at 37 °C, 5%
CO2. The same, single peptide concentration was used for
all experiments. No peptide dose–response analyses were
done.
ELISPOT assay
The IFN-γ ELISPOT and IL-5 ELISPOT assays were
performed using the mouse IFN-γ ELISPOT pair (BD
Biosciences, San Jose, USA) or IL-5 ELISPOT pair (BD
Biosciences, San Jose, USA) in combination with MultiScreen-
IP filter plates (Millipore, Billerica, MA), according to the
instructions of the manufacturer. Cells where stimulated in
200 μl RPMI 1640 (Invitrogen Life Technologies), containing
24 E.A.W. Claassen et al. / Virology 368 (2007) 17–2510% FCS, 1% L-glutamine and 5 μg/ml peptide for 24 h at
37 °C, 5% CO2. ELISPOT plates were analyzed using an
AELVIS ELISPOT reader with ELI.Analyse software (A.EL.
VIS GmbH, Hannover, Germany).
Staining and flow cytometry
The following antibodies were used: anti-CD3 PerCP (145–
2C11), anti-CD4 PE and PerCP (L3T4), anti-CD8 APC and
FITC (Ly-2), anti-CD11a FITC (2D7), anti-CD62 L PE (MEL-
14), anti-IFN-γ FITC (XMG1.2), anti-TNF-α PE (MP6-XT22)
and anti-CD43-FITC (1B11). All antibodies were purchased
from BD Biosciences (San Jose, USA). PE-labeled P261–270 H-
2Kd pentamer constructs were purchased from ProImmune
(Oxford, UK). Intracellular stainings were done using the Cyto-
Fix/CytoPerm solution and Perm/Wash buffer purchased from
BD Biosciences (San Jose, CA) according to the instructions of
the manufacturer. Cells were acquired on a FACScalibur flow
cytometer (BD Biosciences, San Jose, CA) using CellQuest
software. Data analysis was done with CellQuest (BD
Biosciences, San Jose, CA) and FlowJo (TreeStar, Ashland,
OR) software.
Statistics
T cell responses as measured by ELISPOT were compared
using the t test, using two-tailed P values. Statistical analysis of
Kaplan–Meier survival plots was done with the log-rank test.
Prism Graphpad software (GraphPad Software, San Diego, CA)
was used for statistical analysis.
Acknowledgments
The authors wish to thank the animal care workers of the
GDL for biotechnical support and Corlinda ten Brink for
technical assistance. This work was supported by the “Breed-
testrategie”, a research initiative from the University of Utrecht.
References
Antonis, A.F., Schrijver, R.S., Daus, F., Steverink, P.J., Stockhofe, N., Hensen,
E.J., Langedijk, J.P., van der Most, R.G., 2003. Vaccine-induced
immunopathology during bovine respiratory syncytial virus infection:
exploring the parameters of pathogenesis. J. Virol. 77 (22), 12067–12073.
Antonis, A.F., Claassen, E.A., Hensen, E.J., de Groot, R.J., de Groot-Mijnes,
J.D., Schrijver, R.S., van der Most, R.G., 2006. Kinetics of antiviral CD8
T cell responses during primary and post-vaccination secondary bovine
respiratory syncytial virus infection. Vaccine 24 (10), 1551–1561.
Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H.,
Freeman, G.J., Ahmed, R., 2006. Restoring function in exhausted CD8 T
cells during chronic viral infection. Nature 439, 682–687.
Barends, M., de Rond, L.G., Dormans, J., van Oosten, M., Boelen, A., Neijens,
H.J., Osterhaus, A.D., Kimman, T.G., 2004. Respiratory syncytial virus,
pneumonia virus of mice, and influenza Avirus differently affect respiratory
allergy in mice. Clin. Exp. Allergy 34 (3), 488–496.
Blumenthal, R.L., Campbell, D.E., Hwang, P., DeKruyff, R.H., Frankel, L.R.,
Umetsu, D.T., 2001. Human alveolar macrophages induce functional
inactivation in antigen-specific CD4 T cells. J. Allergy Clin. Immunol.
107 (2), 258–264.
Cauley, L.S., Cookenham, T., Miller, T.B., Adams, P.S., Vignali, K.M., Vignali,D.A., Woodland, D.L., 2002. Cutting edge: virus-specific CD4+ memory
T cells in nonlymphoid tissues express a highly activated phenotype.
J. Immunol. 169 (12), 6655–6658.
Chang, J., Braciale, T.J., 2002. Respiratory syncytial virus infection suppresses
lung CD8+ T-cell effector activity and peripheral CD8+ T-cell memory in
the respiratory tract. Nat. Med. 8 (1), 54–60.
Chang, J., Choi, S.Y., Jin, H.T., Sung, Y.C., Braciale, T.J., 2004. Improved
effector activity and memory CD8 T cell development by IL-2 expression
during experimental respiratory syncytial virus infection. J. Immunol. 172
(1), 503–508.
Chapman, T.J., Castrucci, M.R., Padrick, R.C., Bradley, L.M., Topham, D.J.,
2005. Antigen-specific and non-specific CD4+ T cell recruitment and
proliferation during influenza infection. Virology 340 (2), 296–306.
Chi, B., Dickensheets, H.L., Spann, K.M., Alston, M.A., Luongo, C.,
Dumoutier, L., Huang, J., Renauld, J.C., Kotenko, S.V., Roederer, M.,
Beeler, J.A., Donnelly, R.P., Collins, P.L., Rabin, R.L., 2006. Alpha and
lambda interferon together mediate suppression of CD4 T cells induced by
respiratory syncytial virus. J. Virol. 80 (10), 5032–5040.
Claassen, E.A., van der Kant, P.A., Rychnavska, Z.S., van Bleek, G.M., Easton,
A.J., van der Most, R.G., 2005. Activation and inactivation of antiviral CD8
Tcell responses during murine pneumovirus infection. J. Immunol. 175 (10),
6597–6604.
Cook, P.M., Eglin, R.P., Easton, A.J., 1998. Pathogenesis of pneumovirus
infections in mice: detection of pneumonia virus of mice and human
respiratory syncytial virus mRNA in lungs of infected mice by in situ
hybridization. J. Gen. Virol. 79 (Pt 10), 2411–2417.
De Graaff, P.M., Heidema, J., Poelen, M.C., Van Dijk, M.E., Lukens, M.V., Van
Gestel, S.P., Reinders, J., Rozemuller, E., Tilanus, M., Hoogerhout, P., Van
Els, C.A., Van Der Most, R.G., Kimpen, J.L., Van Bleek, G.M., 2004. HLA-
DP4 presents an immunodominant peptide from the RSV G protein to
CD4 T cells. Virology 326 (2), 220–230.
de Graaff, P.M., de Jong, E.C., van Capel, T.M., van Dijk, M.E., Roholl, P.J.,
Boes, J., Luytjes, W., Kimpen, J.L., van Bleek, G.M., 2005. Respiratory
syncytial virus infection of monocyte-derived dendritic cells decreases their
capacity to activate CD4 T cells. J. Immunol. 175 (9), 5904–5911.
de Waal, L., Yuksel, S., Brandenburg, A.H., Langedijk, J.P., Sintnicolaas, K.,
Verjans, G.M., Osterhaus, A.D., de Swart, R.L., 2004. Identification of a
common HLA-DP4-restricted T-cell epitope in the conserved region of the
respiratory syncytial virus G protein. J. Virol. 78 (4), 1775–1781.
Ellis, J.A., Martin, B.V., Waldner, C., Dyer, K.D., Domachowske, J.B.,
Rosenberg, H.F., 2007. Mucosal inoculation with an attenuated mouse
pneumovirus strain protects against virulent challenge in wild type and
interferon-gamma receptor deficient mice. Vaccine 25 (6), 1085–1095.
Domachowske, J.B., Bonville, C.A., Dyer, K.D., Easton, A.J., Rosenberg, H.F.,
2000. Pulmonary eosinophilia and production of MIP-1alpha are prominent
responses to infection with pneumonia virus of mice. Cell Immunol. 200 (2),
98–104.
Grimaldi, E., Claassen, E.A., Michael Lord, J., Smith, D.C., Easton, A.J., 2007.
Stimulation of pneumovirus-specific CD8+ T cells using a non-toxic
recombinant ricin delivery system. Mol. Immunol. 44 (5), 993–994.
Hogan, R.J., Zhong, W., Usherwood, E.J., Cookenham, T., Roberts, A.D.,
Woodland, D.L., 2001. Protection from respiratory virus infections can be
mediated by antigen-specific CD4(+) T cells that persist in the lungs. J. Exp.
Med. 193 (8), 981–986.
Janssen, E.M., Lemmens, E.E., Wolfe, T., Christen, U., von Herrath, M.G.,
Schoenberger, S.P., 2003. CD4+ T cells are required for secondary
expansion and memory in CD8+ T lymphocytes. Nature 421 (6925),
852–856.
Moon, B.G., Takaki, S., Miyake, K., Takatsu, K., 2004. The role of IL-5 for
mature B-1 cells in homeostatic proliferation, cell survival, and Ig
production. J. Immunol. 172 (10), 6020–6029.
Openshaw, P.J., Culley, F.J., Olszewska, W., 2001. Immunopathogenesis of
vaccine-enhanced RSV disease. Vaccine 20 (Suppl 1), S27–S31.
Ostler, T., Hussell, T., Surh, C.D., Openshaw, P., Ehl, S., 2001. Long-term
persistence and reactivation of T cell memory in the lung of mice
infected with respiratory syncytial virus. Eur. J. Immunol. 31 (9),
2574–2582.
Randolph, D.A., Stephens, R., Carruthers, C.J., Chaplin, D.D., 1999.
25E.A.W. Claassen et al. / Virology 368 (2007) 17–25Cooperation between Th1 and Th2 cells in a murine model of eosinophilic
airway inflammation. J. Clin. Invest. 104 (8), 1021–1029.
Rosenberg, H.F., Bonville, C.A., Easton, A.J., Domachowske, J.B., 2005. The
pneumonia virus of mice infection model for severe respiratory syncytial
virus infection: identifying novel targets for therapeutic intervention.
Pharmacol. Ther. 105 (1), 1–6.
Stanciu, L.A., Bellettato, C.M., Laza-Stanca, V., Coyle, A.J., Papi, A., Johnston,
S.L., 2006. Expression of Programmed Death-1 Ligand (PD-L) 1, PD-L2,
B7-H3, and inducible costimulator ligand on human respiratory tract
epithelial cells and regulation by respiratory syncytial virus and type 1 and 2
cytokines. J. Infect. Dis. 193 (3), 404–412.
Stephens, R., Randolph, D.A., Huang, G., Holtzman, M.J., Chaplin, D.D.,
2002. Antigen-nonspecific recruitment of Th2 cells to the lung as a
mechanism for viral infection-induced allergic asthma. J. Immunol. 169
(10), 5458–5467.
Thorpe, L.C., Easton, A.J., 2005. Genome sequence of the non-pathogenic strain
15 of pneumonia virus of mice and comparison with the genome of the
pathogenic strain J3666. J. Gen. Virol. 86 (Pt 1), 159–169.van der Most, R.G., Sette, A., Oseroff, C., Alexander, J., Murali-Krishna, K.,
Lau, L.L., Southwood, S., Sidney, J., Chesnut, R.W., Matloubian, M.,
Ahmed, R., 1996. Analysis of cytotoxic T cell responses to dominant and
subdominant epitopes during acute and chronic lymphocytic choriomenin-
gitis virus infection. J. Immunol. 157 (12), 5543–5554.
Varga, S.M., Braciale, T.J., 2002. RSV-induced immunopathology: dynamic
interplay between the virus and host immune response. Virology 295 (2),
203–207.
Varga, S.M., Wissinger, E.L., Braciale, T.J., 2000. The attachment (G)
glycoprotein of respiratory syncytial virus contains a single immuno-
dominant epitope that elicits both Th1 and Th2 CD4+ T cell responses.
J. Immunol. 165 (11), 6487–6495.
Varga, S.M., Wang, X., Welsh, R.M., Braciale, T.J., 2001. Immunopathology in
RSV infection is mediated by a discrete oligoclonal subset of antigen-
specific CD4(+) T cells. Immunity 15 (4), 637–646.
Zhong, W., Roberts, A.D., Woodland, D.L., 2001. Antibody-independent
antiviral function of memory CD4+ T cells in vivo requires regulatory
signals from CD8+ effector T cells. J. Immunol. 167 (3), 1379–1386.
